Generics companies get green light for Lundbeck drug

The patent for Lundbeck's drug Northera has officially expired in the US, and no less than 12 companies have so far received approval from the US health authorities to market a generic version of the drug.

Photo: Jens Dresling

On Feb. 18, the patent for Lundbeck's Northera officially expired in the US, after which companies are lining up to bite into the market, which the Danish pharmaceutical giant has exclusive rights to up until now.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs